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Due to its pleiotropic effects, the commonly used drug metformin has gained renewed interest among medical researchers. While
metformin is mainly used for the treatment of diabetes, recent studies suggest that it may have further application in anticancer
and antiaging therapies. In this study, we investigated the proliferative potential, accumulation of oxidative stress factors, and
osteogenic and adipogenic differentiation potential of mouse adipose-derived stem cells (MuASCs) isolated frommice treated with
metformin for 8 weeks. Moreover, we investigated the influence of metformin supplementation on mice bone density and bone
element composition. The ASCs isolated from mice who were treated with metformin for 8 weeks showed highest proliferative
potential, generated a robust net of cytoskeletal projections, had reduced expression of markers associated with cellular senescence,
and decreased amount of reactive oxygen species in comparison to control group. Furthermore, we demonstrated that these
cells possessed greatest osteogenic differentiation potential, while their adipogenic differentiation ability was reduced. We also
demonstrated that metformin supplementation increases bone density in vivo. Our result stands as a valuable source of data
regarding the in vivo influence ofmetformin onASCs and bone density and supports a role formetformin in regenerativemedicine.
1. Introduction
Over the past several years, the pleiotropic effects of met-
formin (N, N󸀠-dimethylbiguanide), a commonly used drug
for the treatment of type 2 diabetes mellitus (T2DB),
have gained interest among both clinicians and medical
researchers. Metformin belongs to the group of biguanide
drugs that are mainly prescribed for insulin resistance (IR),
for obesity, and for patients suffering from polycystic ovarian
syndrome (POS) [1]. The general systemic effects of met-
formin involve the reduction of glucose production in the
liver and increased insulin sensitivity in peripheral tissues.
Metformin has also been proposed as a calorie restriction
mimetic (CRM) that has been shown in combination with
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calorie restriction, to reduce morbidity and mortality in
both healthy and tumorigenic mice, thus increasing overall
lifespan [2].
In the field of regenerative medicine, major scientific
interest is focused on the cytophysiological characteristics
and clinical application of mesenchymal stem cells (MSCs).
Those cells are found inmany types of adult tissues, including
bonemarrow and adipose tissue [3]. Although adipose tissue-
derived stem cells (ASCs) share similar characteristics with
bone marrow mesenchymal stem cells (BMSCs), they have
several advantages over BMSCs. They are easily accessible
withminimal invasive harvesting procedure and the isolation
yields a great number of cells, crucial for effective stem cell
therapies and bone engineering.
Furthermore, it has been shown that metformin may
inhibit the growth of tumor cells and thus may potentially
find wide application in anticancer therapies [4–8]. Hirsch
et al. [9] demonstrated that metformin inhibits cellular
transformation and selectively kills cancer stem cells in
genetically distinct breast cancer cells lines. The inhibitory
effect of metformin on tumor cells in vitro is associated not
only with its cytostatic properties, but also with proapoptotic
actions in the tumor cells [10]. To date, the signaling pathways
of metformin’s mechanism of action have not been fully
understood and require further study. However, it seems
that metformin affects insulin-like growth factor (IGF) path-
ways by activation of 5󸀠-adenosinemonophosphate-activated
protein kinase (AMPK), which plays a key role in insulin
signaling and energy sensing [11]. Moreover, it has been
shown that, in the context of atherosclerosis, metformin
inhibits NF-𝜅B activation, decreases C-reactive protein levels
[12], and inhibits the inflammatory response via a pathway
involving AMPK and the tumor suppressor PTEN [13].
Moreover, recent studies have indicated antioxidative
properties of metformin. Increased production of the intra-
cellular level of reactive oxygen species (ROS) results from
the imbalance of the antioxidant scavenger enzymes that
metabolize free radicals. The antioxidant enzymes include
manganese superoxide dismutase (MnSOD), copper and
zinc (Cu/Zn) SOD, catalase, and glutathione peroxidase.
When the level of ROS exceeds the defense mechanisms,
a cell is said to be in a state of “oxidative stress” [14]. The
enhanced production of ROS during environmental stresses
can pose a threat to cells by causing peroxidation of lipids,
oxidation of proteins, and damage to nucleic acids, ultimately
leading to death of the cells. Thus dealing with excessive
ROS may improve cellular metabolism and in consequence
increase the lifespan. It was also shown that metformin
exerted intracellular antioxidant properties by decreasing
ROS production through the inhibition of protein kinase C
activity [15]. Recent studies indicate that its primary effect is
inmitochondria, where it interferes with respiratory complex
I and reduces ATP production, leading to the activation of
AMP kinase [16].
However, the potential role of metformin in reducing
ROS in ASC is still not well established.
It has also been reported that metformin can induce
MC3T3-E1 osteoblastic cell differentiation and bone matrix
synthesis via AMPK activation and subsequent induction of
endothelial nitric oxide synthase (eNOS) and bone morpho-
genetic protein-2 (BMP-2) expression [17, 18].Metforminwas
also found to enhance rat osteoblasts proliferation, increase
alkaline phosphatase activity, and increase the number of
formed mineralized nodules. Our group recently showed
that metformin, in a dose-dependent manner, affects the
viability, morphology, and ultrastructure of mouse bone
marrow-derived multipotent mesenchymal stromal cells and
the Balb/3T3 embryonic fibroblast cell line [19]. We have also
demonstrated that the expression of tandem gene H19/IGF2,
as well as Oct4, a pluripotent stem cell marker, in part
correlates with particular dosage application of metformin in
vitro. Additionally, we found a significant correlation between
the activity of the ASCs and osteopontin at the mRNA and
protein level in vitro and in vivo. The mounting evidence
indicates that the range of metformin actions may be signif-
icantly wider than once thought, and thus the application of
metforminmay open new avenues in the treatment of various
medical conditions [20, 21].
Bone development is a complex and dynamic process
involving several different mechanisms that maintain the
balance between bone formation and bone resorption. This
balance might be affected by different factors including phys-
ical activity, endogenous hormones, or drugs [22]. Essential
to this balance and to the formation of the skeletal system
is proosteoblastic differentiation of bone marrow stem cells,
osteoclast activity, and the osteoblast-adipocyte relationship.
Recently, it has been demonstrated that the complement
system plays an important role in both bone development
and homeostasis and specifically influences osteoblast and
osteoclast activity [23]. Moreover, it has been shown that
complement plays a role in the bone repair process, thusmak-
ing a bridge between skeletal and immunological systems.
Bearing in mind that previous research has indicated a
proosteogenic effect ofmetformin onBMSCs or commitment
cell lines in vitro, we became interested in the effect of
metformin on the osteogenic potential of mice, as well as
the effects of metformin on bone in vivo. It has been shown
that metformin prevents bone loss induced by ovariectomy
in rats [24], suggesting that metformin confers a protective
effect against bone loss. Further research on rats showed
that 2 weeks of metformin supplementation led to increased
trabecular volume, osteocyte density, and osteoblast number
in femoral metaphysis [25]. Wang et al. [26], using insulin-
resistantmice, also showed that 6weeks ofmetformin admin-
istration protects femoral bone architecture [26]. However,
little is known about the effects of metformin on bone
trabecular architecture and bone density in healthy mice.
The aim of our study was to investigate the effects of
metformin on ASCs osteogenic differentiation potential in
vitro and on bone density andmineralization in healthymice.
2. Materials and Methods
All reagents used in this experiment were purchased from
Sigma-Aldrich (Poland), unless indicated otherwise.
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2.1. Experimental Animals. The experiment was performed
on 4-week-old C57BL/6 mice (𝑛 = 18). All mice were housed
three per cage in an ultraclean facility on ventilated racks
and were provided with food and water ad libitum during th
experiment period. Mice received a standard diet with 4.2%
fat (Morawski, Labofeed H, Poland) and were maintained
on a 12-h light-dark cycle at 22 ± 0.2∘C. The animals were
purchased from the Animal Laboratory House, Wroclaw
Medical School, and housed in the Animal Experimental
Laboratory (Wroclaw Medical School, Wroclaw, Poland).
The animals used in the study were divided into two
groups: (a) controlmice receiving drinkingwater only [𝑛 = 9]
and (b) the group receiving metformin in drinking water at
concentration equal to 2.8mg/day (Metformax 850; Teva
Pharmaceuticals, Poland) for 8 weeks [𝑛 = 9]. Water
was changed every two days. After the experiment, the
mice were fasted for 24 h. Body weight measurement was
carried out using electronic scale (RADWAG PS/C1 series,
Poland). Bloodwas collected from the animals using a cardiac
puncture method. Biochemical analysis of blood samples,
such as glucose and lipidsmeasurements, was performedwith
Erba XL 300 platform (Erba Diagnostics Mannheim GmbH,
Germany). After euthanasia of the animals, abdominal sub-
cutaneous adipose tissue, as well as both tibia bones, was
collected from each animal.
Cells or tissues obtained from animals treated with drug
for 8 weeks are designated as the 8-week metformin (Met 8)
group and from the control group were designated as control.
2.2. Isolation of Mice Adipose-Derived Mesenchymal Stem
Cells (MuASCs) from Adipose Tissue. The MuASCs were
isolated from subcutaneous adipose tissue of C57BL/6 mice
(𝑛 = 9 Met 8 mice, 𝑛 = 9 control mice). Cells were isolated
using a protocol previously described by Grzesiak et al. [27].
Tissue samples were placed in sterile Hanks’ balanced salt
solution (HBSS), containing 1% of antibiotic/solution (P/S/A:
Penicillin/Streptomycin/Amphotericin B) and washed exten-
sively to remove contaminating debris and erythrocytes.
After removing blood vessels, the tissue was cut into small
pieces using surgical scissors. Aspirates were then transferred
into sterile tubes and treated with collagenase type I enzyme
(1mg/mL) in PBS for 40min at 37∘C with gentle agitation.
The obtained tissue homogenate was then centrifuged for
10min at 1200×g.The supernatant was then discarded, while
the cell pellet was resuspended in culture media and plated
onto a conventional tissue culture flask.
2.3. Cells Culture. All stages of the experiment were per-
formed under aseptic, standardized culture conditions (37∘C,
5% CO
2
). Primary cultures were plated on T25 culture
flasks in culture media consisting of Dulbecco’s Modified
Eagle’s Medium (DMEM) with nutrient F-12 Ham, 10% of
Fetal Bovine Serum (FBS), and 1% solution of P/S/A. The
medium was changed every two days, while passage of cells
was performed after reaching 80–90% confluence. Prior to
the experiment, cells were passed three times using trypsin
solution (TrypLE; Life Technologies, Carlsbad, USA) in
accordance with manufacturer’s protocol.
2.4. Immunophenotyping of MuASCs andMultipotency Assay.
Isolated cells were characterized by the expression of follow-
ing markers: CD29, CD44, CD45, CD73, and CD105. Prior to
staining, cells were cultivated onto 24-well dishes designated
for immunofluorescence preparations. For each staining,
cultures were run in triplicate. The following antibodies
were used in the experiment: rabbit anti-mouse integrin-b-1
(CD29), dilution 1 : 100; rabbit anti-mouse CD44 (R&D Sys-
tems, Minneapolis, USA), dilution 1 : 100; rabbit anti-mouse
CD45, dilution 1 : 100; rabbit anti-mouse NT5E (CD73),
dilution 1 : 200; rabbit anti-mouse endoglin (CD105), dilution
1 : 200. Secondary antibody conjugated with atto-488 fluores-
cence label goat anti-mouse IgG atto-488 was diluted 1 : 400.
Immunocytochemistry was performed in accordance with
the manufacturer’s instructions. Briefly, cells were incubated
with certain primary antibodies overnight, while incubation
with secondary antibodies lasted 1 hour and was performed
in 37∘C, in the dark. To assess the binding specificity of
secondary antibodies, negative controls were included. To
visualize cells nuclei, specimens were counterstained with
4󸀠,6-diamidino-2-phenylindole (DAPI). The samples were
imaged using an inverted fluorescence microscope (AxioOb-
serverA1, Carl Zeiss, Jena, Germany) and captured with
Canon PowerShot. Multipotency of MuASCs was confirmed
by adipogenic and osteogenic differentiation of cells, cultured
in commercially available media (StemPro, Life Technolo-
gies) onto 24-well plates. Adipogenic differentiation was con-
firmed with Oil Red O, to visualize lipid droplets. Osteogenic
differentiation was confirmed with Alizarin Red staining of
the extracellular matrix mineralization. Experiments were
carried out simultaneously and performed in triplicate.
2.5. Cell Viability and Colony Forming Efficiency Assay. For
the assays, cells were plated onto 24-well plates and inoculated
with a 0.5mL volume of culturemedium at a concentration of
2×10
4 cells per well.The number of viable cells in the culture
was evaluated using resazurin-based assay kit (Alamar Blue)
in accordance with the manufacturer’s instruction after 1,
2, 5, and 7 days of cell culture. Briefly, to perform the
assay, the culture medium was collected and replaced with a
medium containing 10% of the dye. Cells were then incubated
for 2 hours at 37∘C, followed by supernatant collection.
Absorbance levels of the supernatants were measured spec-
trophotometrically using 96-well microplate reader (Spec-
trostar Nano, BMG Labtech, Ortenberg, Germany). The dye
reduction was evaluated at a wavelength of 600 nm and a
reference wavelength of 690 nm. Each test included a blank
that consisted of completemediumwith dye.The cell number
was obtained from the test data and allowed to calculate
the population doubling time (PDT), as well as proliferation
factor (PF).
The calculated values of PF reflect the activity of the
experimental group (Met 8) in relation to the control group,
giving an arbitrary value equal to 1. A PF value higher than 1
indicated increased cellular activity, while a PF lower than 1
showeddecreased proliferation potential. PDTwas calculated
using online software (http://www.doubling-time.com/).
To evaluate the ability of cells to form colonies, a colony
forming efficiency (CFE) assay was performed. Cells were
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seeded onto 6-well plates at an initial density of 1×102 perwell
and inoculated in culture media (DMEM with nutrient F-12
Ham, 10% FBS, 1% P/S/A). After seven days of propagation,
cells were washed with 4% ice-cold paraformaldehyde and
stained with pararosaniline. Colonies of more than 50 cells
were counted, and the efficiency of colony forming was
calculated using the formula presented as follows [28]:
CFUfs [%] = the number of colonies
initial cell number
× 100%. (1)
2.6. Evaluation of Cell Morphology, Ultrastructure, and Senes-
cence Markers. Cell morphology, cellular composition, and
culture growth pattern were analyzed using an inverted,
fluorescence microscope (Axio ObserverA1, Zeiss, Jena, Ger-
many) and a scanning electron microscope (SEM; EVO LS15,
Zeiss, Jena, Germany).
The morphology of cells was evaluated on the 7th
(standard culture), 12th (adipogenic stimulation), and 18th
(osteogenic stimulation) days. Prior to observation, cells were
cultured on 24-well plates. After fixation in 4% ice-cold
paraformaldehyde (40min), cells membranes were perme-
abilized using 0.1% Triton X-100 for 15min. After washing
withHBSS, cells were stainedwith atto-565 labeled phalloidin
for 40min to visualize actin filaments. Cells were then
washed again with HBSS three times and the nuclei were
subsequently counterstained with diamidino-2-phenylindole
(DAPI) for 5min. During fluorescence staining, cells were
incubated at room temperature in the dark.
To confirm osteogenesis and adipogenesis, Alizarin Red
and Oil Red O staining were applied, respectively. First
the culture media were removed, and the cells were then
washed with HBSS followed by treatment with 4% ice-cold
paraformaldehyde for 10min. To visualize the extracellular
mineralized matrix, cells were incubated with 2% Alizarin
Red solution for 10min. After dye discarding, cells were
washed a few times with distilled water. For intracellular
lipid droplets visualization, paraformaldehyde was replaced
with 60% isopropanol and the cells were incubated with it
for 5min. Then the cells were rinsed with distilled water
and Oil Red O solution was added for 15min, followed by
hematoxylin counterstaining for 1min. Images were captured
using a Canon PowerShot camera.
Detailed cells morphology was evaluated using SEM.
Cells were rinsed with distilled water and dehydrated in a
graded ethanol series (concentrations from 50% to 100%,
every 5min). Samples were then sprinkled with gold (Scan-
Coat 6, Oxford), transferred to the microscope chamber, and
observed using SE1 detector, at 10 kV of filament tension.
Additionally, the number of bone nodules, the size of the nod-
ules, and the calcium and phosphorus concentration within
the nodules were analyzed by SEM with energy dispersive
X-ray analysis (SEM/EDX). A QUANTAX detector (Brüker,
Billerica, USA) with 10 kV of filament tension was used to
perform a line scan analysis of randomly selected cells. The
obtained values of calcium and phosphorus deposition were
presented as weight percentage (wt%).
To evaluate amounts of viable and dead cells, a Cellstain
Double Staining Kit was applied. Live cells were stained with
Calcein-AMand emitted a green fluorescence signal, whereas
dead cell nuclei were stained with Propidium Iodide and
emitted a red/orange fluorescence. Cells were then observed
using fluorescence microscopy. All procedures were per-
formed in accordance with the manufacturer’s instructions.
Immunofluorescence staining for caspase-3 was performed
using anti-caspase 3 antibodies (anti-caspase-3 active anti-
body produced in rabbit, cat number C8487). Prior to investi-
gation of senescence-associated 𝛽-galactosidase (𝛽-gal), cells
were stained using a commercially available kit (Senescence
Cells Histochemical Staining Kit) following manufacturer’s
protocol.
2.7. Analysis of Oxidative Stress and Superoxide Dismutase
Activity (SOD). To evaluate stress levels, the cells were
cultured in medium without phenol red for 7 days and
the tests were performed on the 7th day. Nitric oxide
(NO) concentration was assessed with the Griess Reagent
Kit (Life Technologies), superoxide dismutase (SOD) was
assessed by SOD Assay Kit, and the level of reactive oxygen
species (ROS) was estimated with a 5-(and-6)-chloromethyl-
2󸀠,7󸀠-dichlorodihydrofluorescein diacetate (H2DCF-DA, Life
Technologies) solution. All procedures were performed in
duplicate in accordance with the manufacturer’s protocols.
2.8. Evaluation of Osteogenic and Adipogenic Differentiation
Potential of MuASCs. For the in vitro osteogenic and adi-
pogenic assays, cells were planted onto 24-well plates at
an approximate density of 2 × 104 cells per well. Prior
to osteogenic differentiation of MuASCs, cells were cul-
tured in STEMPRO Osteogenesis Differentiation Kit (Life
Technologies, Carlsbad, USA) for a period of 18 days. For
adipogenic differentiation, cells were cultured in STEM-
PRO Adipogenesis Differentiation Kit (Life Technologies,
Carlsbad, USA) for 12 days. The differentiation media were
supplemented with 1% of P/S/A and changed every two days.
Cultures expanded in standard culture media (DMEM with
nutrient F-12 Ham, 10% FBS, 1% P/S/A) served as a control
(nonstimulated), which allowed determining effectiveness of
the differentiation process. All procedures were performed in
accordance with the manufacturer’s instructions.
2.9. Detection of Extracellular Form of Osteopontin (OPN),
Osteocalcin (OCL), and Bone Morphogenetic Protein-2 (BMP-
2) with Enzyme-Linked Immunosorbent Assay (ELISA). The
investigated markers were detected in the supernatants col-
lected at the last day of the differentiation process, the 18th
day of osteogenic stimulation and the 12th day of adipogenic
stimulation. The presence of osteopontin (OPN) was deter-
mined using Mouse/Rat Osteopontin Quantikine ELISA
Kit (R&D Systems, Minneapolis, USA), whereas osteocalcin
(OCN) was assessed with the Mouse Gla-Osteocalcin High
Sensitive EIA Kit (Takara, Otsu, Japan). The level of bone
morphogenetic protein (BMP) was investigated with the
Mouse BMP-2 Quantikine ELISA Kit (R&D Systems, Min-
neapolis, USA). All procedures were performed according to
themanufacturer’s protocol.The amount of detected proteins
was expressed as ng/mL of supernatant.
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Table 1: Sequences of primers used in qPCR. OCN: Osteocalcin; BMP-2: Bone morphogenetic protein-2; ADPQ: Adiponectin, B2M: beta 2
microglobulin.
Gene Primer Sequence 5󸀠-3󸀠 Amplicon length (bp) Accesion no.
OCN F: GGTGCAGACCTAGCAGACACCA 100 NM 001032298.2
R: CGCTGGGCTTGGCATCTGTAA
BMP-2 F: CTACAGGGAGAACACCCGGA 280 NM 007553.3
R: GGGGAAGCAGCAACACTAGAA
ADPQ F: CCTGGAGAGAAGGGAGAGAAA 209 NM 009605.4
R: CGAATGGGTACATTGGGAAC
B2M F: CATACGCCTGCAGAGTTAAGCA 73 NM 009735.3
R: GATCACATGTCTCGATCCCAGTAG
2.10. Analysis of Gene Expression: Real-Time Reverse Tran-
scription Polymerase Chain Reaction (qRT-PCR) of OPN,
BMP-2, and Adiponectin (ADPQ). After osteogenic stimula-
tion, on the 18th day of culture, the cultures were rinsed with
HBSS and lysed in a culture dishwith 0.5mLof TRIReagent.
The total RNA was isolated using a phenol chloroform
method. The resulting samples were then diluted in DEPC-
treated water. The quantity and quality of the total RNA were
determined using a nanospectrometer (VPA biowave II). To
remove any traces of genomic DNA, samples were digested
using DNase I RNase-free kit (Thermo Scientific, Waltham,
USA). Each reaction was performed with 100 ng of total
RNA, which was then transcribed to complementary DNA
(cDNA) with the Moloney murine leukemia virus reverse
transcriptase (M-MLV RT), provided with the Tetro Reverse
Transcriptase kit (Bioline, London, UK). Both RNA purifica-
tion and cDNA synthesis were performed following theman-
ufacturers protocol, using a T100 Thermo Cycler (Bio-Rad,
Hercules, USA). Quantitative RT-PCR was performed in a
total volume of 20𝜇L using the SensiFast SYBR&Fluorescein
Kit (Bioline, London, UK).The primer concentration in each
reaction equaled 500 nM, and the primer sequences used for
each specific reaction are listed in Table 1. The analysis was
performedusingCFXConnectTMReal-TimePCRDetection
System (Bio-Rad, Hercules, USA). To confirm the specificity
of the reaction products, an analysis of the dissociation curve
was performed.The value of the threshold cycle (Ct) was used
to calculate the fold change in relation to the expression of the
housekeeping gene, B2M (beta-2 microglobulin).
2.11. Ex Vivo Analysis of Bone Mineral Concentration and
Density by Microtomography (𝜇CT) and SEM-EDX Calcium
Deposition Analysis. Prior to performing 𝜇CT analysis, the
bone samples were fixed in 4% formaldehyde in PBS for 48 h.
Specimens were then dehydrated in an increasing ethanol
gradient of 50%, 60%, 70%, 80%, 96%, and 100% and then
analyzed in 𝜇CT.
The tomographic studies were carried out in the Labo-
ratory of Micro and Nano Tomography (LMINT), Faculty
of Physics and Applied Computer Science, AGH Univer-
sity of Science and Technology, Krakow, Poland. The 𝜇CT
measurements were performed using a Nanotom 180N (GE
Sensing & Inspection Technologies, Phoenix X-ray GmbH).
The machine is equipped with a nanofocus X-ray tube with
a maximum 180 kV voltage. The tomograms were registered
using a Hamamatsu 2300 × 2300 pixel 2D detector. The
reconstruction of measured objects was performed using
datosX ver. 2.1.0 (GE) with the use of a Feldkamp algorithm
for cone beam X-ray CT [29]. The postreconstruction data
treatment was performed using VGStudio Max 2.1 [30] and
free Fiji software [31] with the BoneJ plugin [32].
All examined specimens were scanned at 70 kV of source
voltage and 200𝜇A, with a 360-degree rotation of the spec-
imen in 1400 steps. The exposure time was 500ms, with a
frame averaging of 3 and image skip of 1 applied, resulting
in a scanning time of 60 minutes. The reconstructed images
had a voxel size of 5 𝜇m3.
For SEM-EDX analysis, the femoral bones were fixed in
2.5% glutaraldehyde for one hour, washed in distilled water,
dehydrated in a graded ethanol series, sputtered with carbon
(ScanCoat 6, Oxford), and imaged using an SEM at 10 kV of
filament’s tension. Additionally, specimens were prepared for
EDX analysis according to the method described previously
by our laboratory [33]. Observations were performed at a
filament tension of 10 kV.The detection ofmineralizedmatrix
was performed using SEM combined with EDX (Bruker,
Coventry, UK) to analyze the surface distribution of calcium
and phosphorus. The values obtained were presented as
weight percentage (wt%).
2.12. Statistical Analysis. All experiments were performed
with 𝑛 = 3 or more. Statistical analysis was performed
usingGraphPad Prism 5 software (La Jolla, USA). Differences
between groups was determined using one-way analysis of
variance (ANOVA) with post hoc Tukey’s multiple compar-
ison or Student’s 𝑡-test. Differences with a probability of 𝑝 <
0.05 were considered significant.
3. Results
The clinical characteristics of the C57BL/6 mice included in
the study, assessed following the 24 h of fasting at the end of
the experiment, are presented in Table 2.
3.1. Immunophenotyping Characterization of IsolatedMuASCs
and Multipotency Assay. In order to confirm multipotent
character of isolated ASCs, immunohistochemical staining
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CD29+
CD44+
CD73+
Staining results Negative controls 
CD105+
CD45−
Figure 1: Results of MuASCs immunophenotyping. Obtained cells were positive for the mesenchymal markers CD29, CD44, CD73, and
CD105 and show lack of expression for the hematopoietic marker CD45. Each marker was stained with a specific antibody and secondary
antibodies conjugated with atto-488; nuclei were counterstained with DAPI. Magnification ×100, scale bar: 250 𝜇m.
and multipotency assays were performed. Immunohisto-
chemical staining revealed that MuASCs population did not
express CD45 hematopoietic marker (Figure 1). In contrast,
we observed positive reactions for mesenchymal markers
which are specific to multipotent stromal cells including
CD29, CD44, CD73, and CD105 (Figure 2). Moreover, the
multipotent character of isolated MuASCs was confirmed by
positive adipogenic and osteogenic differentiation (Figure 2).
Formation of extracellular matrix mineralization was visu-
alized by Alizarin Red staining (Figure 2(c)). In addition,
Oil Red O staining was performed to reveal the formation
of intracellular lipid droplets (Figure 2(b)). Cells cultured in
standard medium served as a control (Figure 2(a)).
3.2. Proliferation Factor (PF), Population Doubling Time
(PDT), and Colony Forming Efficiency (CFE) of MuASCs dur-
ing Seven-Day Viability Test. The proliferation of MuASCs
was evaluated after 1st, 2nd, 5th, and 7th days of culture. The
viability characteristics of MuASCs including PF, PDT, and
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Standard medium
Mu ASCs culture in: 
(a)
Adipogenic medium
Mu ASCs culture in: 
(b)
Osteogenic medium
Mu ASCs culture in: 
(c)
Figure 2: Results of multipotency assay. Morphology of MuASCs cultured in standard (a), adipogenic (b), and osteogenic (c) conditions.
Calcium deposits in mineralized extracellular matrix were visualized with Alizarin Red staining, while lipid droplets formed in adipogenic
stimulation with Oil Red O. The images included in the figure were chosen to be representative. Magnification ×100, scale bar: 250 𝜇m.
Table 2: Clinical characteristics of C57BL/6 mice.
Parameters Control group(𝑛 = 9)
Metformin 8
weeks (𝑛 = 9)
Body weight (g) 19.4 ± 0.55 22.26 ± 1.1
Fasting blood glucose
(mmol/L) 13.6 ± 0.1 16 ± 0.08
Fasting serum
triglyceride (mmol/L) 0.613 ± 0.018 1.25 ± 0.01
Fasting serum
cholesterol (mmol/L) 1.34 ± 0.01 1.84 ± 0.02
CFE were assessed in comparison to the control group. The
analysis of cytophysiological activity of theMet 8 cells showed
proliferation activity that was decreased after 24 hours of
propagation. However, this was followed by a significantly
accelerated proliferation on the 2nd, 5th, and 7th day of
culture. The highest PF was recorded on 5th day (𝑝 < 0.001)
of experimental culture (Figure 3(a)).
The proliferation assay analysis showed that metformin
taking contributed to the change in PDT. The control group
reached PDT in 160.4 ± 41.9 h. Interestingly, the time needed
to double the population of MuASCs was considerably
reduced in Met 8 group (𝑝 < 0.05), which was only 92.58 ±
5.8 h (Figure 3(b)).
ASCs plated on low density tend to form colonies origi-
nated from a single cell. It was found that cells from the Met
8 group displayed a significantly (𝑝 < 0.05) higher CFE than
the control group (Figure 3(c)).
3.3. Evaluation of MuASCs Morphology. During the initial
stage of culture (from day one) we observed the formation
of embryonic-like nodules (Figures 4(a) and 4(f)), which
displayed the largest morphology in the Met 8 group. The
control culture of MuASCs was characterized by large, flat,
and irregularly shaped cells. The cytoskeleton of those cells
was well developed, and DAPI staining revealed centrally
positioned nuclei (Figures 4(b) and 4(c)). SEM pictures
revealed few actin projections, filopodia and microvesicles
(MVs) that were located near to nucleus, as well as on the
edge of the cell body (Figures 4(d) and 4(e)).
In the Met 8 group, we observed more cells with a
fibroblast-like shape and the embryonic-like nodules were
of greatest size. Moreover, the size of the cells seemed to be
smaller. No apoptotic bodies were observed and the actin
cytoskeleton network was well organized (Figures 4(g) and
4(h)).The number of cells was visibly higher than in the other
groups. The SEM imaging allowed visualization of multiple,
thin cellular projections (Figure 4(i)) and rich production of
MVs (Figure 4(j)).
3.4. Evaluation of Senescence Markers. To evaluate the per-
centage of dead cells in each group, we used a Cellstain
Double Kit. Calcein-AM/Propidium Iodide staining revealed
that the number of dead cells was significantly reduced in the
Met 8 group (Figure 5(a)(V, VI)) in comparison to the control
(Figure 5(a)(I, II)). To determine if a decrease in cell growth
was connected to an increased apoptosis level, we examined
the activity of caspase-3 by immunofluorescence technique.
The obtained pictures showed that the greatest fluorescence
signal was in the control group (Figure 5(a)(III)), with the
signal decreasing in theMet 8 group (Figure 5(a)(VII)), where
the lowest activity of caspase-3 was observed.
We also performed staining for senescence-associated 𝛽-
galactosidase (𝛽-gal).The amount of blue, 𝛽-gal positive cells
was higher in the control (Figure 5(a)(IV)) than in the Met 8
group, where we noticed a reduction in the number of 𝛽-gal
positive cells (Figure 5(a)(VIII)).
Moreover, to provide quantitative data, percentage of
cells positive for both caspase-3 (Figure 5(b)) and 𝛽-gal
(Figure 5(c)) was calculated. Both markers were decreased in
Met 8 group.
3.5. Oxidative Stress Accumulation and SOD Activity. To
evaluate the effect ofmetformin on accumulation of oxidative
stress inMuASCswe investigated the levels of reactive oxygen
species (ROS) and nitric oxide (NO) in those cells. The
amount of both, ROS (Figure 6(a)) and NO (Figure 6(b)),
was significantly decreased in cells obtained from animals
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treated with metformin (𝑝 < 0.05 and 𝑝 < 0.001, resp.). To
investigate the antioxidative defense of MuASC, the activity
of superoxide dismutase (SOD) was assessed. We observed
thatmetformin supplementation positively affects the activity
of SOD, as it was significantly increased in Met 8 group
(Figure 6(c), 𝑝 < 0.05).
3.6. Proliferation Factor (PF) and PDT during Osteogenic Dif-
ferentiation. The PF, as well as the PDT, was analyzed during
the 18-day period of culturing MuASCs in osteogenesis-
inducing medium. Obtained data showed that metformin
supplementation influenced both the PF and PDT. The pro-
liferation of MuASCs from the Met 8 group was decreasing
during the first six days of propagation and reached the
lowest value on the 6th day (𝑝 < 0.001). After that, the
proliferation activity was stabilized. Significant differences
from controls were observed only later, on the last two days
of the experiment, the 16th (𝑝 < 0.01) and 18th (𝑝 < 0.05)
days (Figure 7(a)).
The estimation of PDT showed that the time needed to
double the population in the Met 8 group was significantly
increased (𝑝 < 0.05) in comparison to control culture
(Figure 7(b)).
3.7. The Morphology of Osteoblasts Originated from MuASCs.
After osteogenic induction, cell morphology shifted from
typical fibroblast-like cells to more flattened and cuboidal
cells. Moreover, cytoskeletal projections became shorter.
After 18 days of propagation, bone nodules became visible
and showed strong black/red signal after Alizarin Red stain
was applied (Figure 7(c)(II, V)). Characteristic osteoblast-
like cells were observed in each of the experimental groups;
however, the cells in Met 8 group displayed the most effective
osteogenesis (Figure 7(c)(IV, V, VI)). In this group, bone
nodules were the largest in size, and Alizarin Red dye
absorption was most abundant.
The lowest efficiency of osteogenic induction was
observed in control group, where nodule diameters were
Oxidative Medicine and Cellular Longevity 9
Control Metformin 8 weeks
D
A
PI
D
A
PI
/P
ha
llo
id
in
1s
t d
ay
7t
h 
da
y
lp
mvs
lp
fp
fp
mvs
SE
M
SE
M
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
(j)
Figure 4: Morphology and cellular composition of MuASCs evaluated on 7th day of culture; light microscope (a, f), staining for DAPI (b, g),
DAPI/phalloidin merged (c, h), and SEM (d, e, i, j) images. Morphological features were indicated with proper abbreviations: fp: filopodia,
lp: lamellipodia, and mvs: microvesicles. Magnification: DAPI ×50, scale bar: 250 𝜇m; DAPI/phalloidin ×100, scale bar: 250 𝜇m; SEM ×5000,
scale bar 2 𝜇m.
10 Oxidative Medicine and Cellular Longevity
Control Metformin 8 weeks
lc
(I) (V)
dc
(II)
dc
(VI)
Cas-3
Cas-3
(III) (VII)
Ca
lc
ei
n-
A
M
P. 
Io
di
de
Ca
sp
as
e-
3
𝛽-gal
𝛽-gal
(IV) (VIII)
𝛽
-g
al
ac
to
sid
as
e
lc
Cas-3
𝛽-gal
(a)
0
5
10
15
20
25 Cas-3 positive cells
(%
)
∗∗
(b)
0
5
10
15
20 𝛽-gal positive cells
(%
) ∗
(c)
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much smaller, and calcium deposits absorbed a smaller
amount of Alizarin Red dye (Figure 7(c)(I, II, III)).
Interestingly, in the Met 8 group we observed the lowest
number of bone nodules (Figure 7(d)); however, they
reached the greatest size (Figure 7(e)). Furthermore, calcium
deposition was significantly higher in the Met 8 group,
compared to the control group (Figure 7(f), 𝑝 < 0.001).
The obtained data suggest that metformin supplementation
increases MuASCs osteogenic differentiation potential and
increases its effectiveness.
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3.8. Extracellular Identification of OPN, OCN, BMP-2,
and RT-PCR for OPN and BMP-2. On the 18th day of
osteogenic stimulation, quantitative analysis of extracellular
OPN showed increased levels in the Met 8 (Figure 8(a),
𝑝 < 0.001) group in comparison to the control culture. Like
OPN,OCN concentrationwas also affected by themetformin
supplementation. The OCN concentration was increased in
the Met 8 (𝑝 < 0.01) group (Figure 8(b)). BMP-2 was also
increased in Met 8 group, although without statistical sig-
nificance (Figure 8(c)). Moreover RT-PCR analysis revealed
increased mRNA levels of both OPN (Figure 8(d), 𝑝 < 0.05)
and BMP-2 (Figure 8(e), 𝑝 < 0.01) in Met 8 group.
3.9. Proliferation Factor (PF), PDT, Morphological Changes,
and ADPQ Expression during Adipogenic Differentiation.
The PF, as well as the PDT, was estimated during a 12-day
period of culturing cells in adipogenic-inducing medium.
MuASCs fromMet 8 group showed decrease in PF compared
to the control group (Figure 9(a)). The highest PF value
was observed on the 2nd day, and from that time point a
general decreasing tendency was observed. The PDT was
also increased in metformin group and showed a significant
difference (𝑝 < 0.05) in comparison to the control culture, as
it was reduced by approximately 35% (Figure 9(b)).
Adipogenic differentiation was demonstrated by the
accumulation of intracellular lipid droplets, indicated by Oil
Red O staining on 12th day of culture (Figure 9(c)(III, VI)).
In the control group, we observed the greatest amount of
lipid droplets. The ratio of red staining area was significantly
decreased in metformin group, where adipocytes displayed
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a smaller size and were reduced in number (Figure 9(c)(VI)).
Furthermore, DAPI (Figure 9(c)(I, IV)) and phalloidin (Fig-
ure 9(c)(II, V)) staining revealed that cells from the control
group became enlarged and spread out and simultaneously
decreased the number of cytoskeletal projections. Moreover,
we calculate percentage of area stained with Oil Red O
(Figure 9(d)) and it was significantly reduced in Met 8 group
(𝑝 < 0.01). Using RT-PCR we also assessed the expression
of adiponectin mRNA, which was reduced in Met 8 group
(Figure 9(e), 𝑝 < 0.001). The obtained data suggests that
metformin inhibits adipogenic differentiation of MuASCs.
3.10. Ex Vivo Analysis of Bone Mineral Concentration and
Density. The morphology of murine tibia bones assessed by
Nano-CT is shown in Figure 10(a): control group (I, II)
and Met 8 (III, IV), respectively. Using Nano-CT, we also
evaluated bone density on certain parts of the bone (scanning
began from the proximal epiphysis, in the direction marked
in Figure 9 by the white arrows). The greatest bone density
was observed inMet 8, especially in the proximal 1–6mmarea
of epiphysis, in comparison to other groups (Figure 10(b)).
The smallest medullary cavity observed in the Met 8 group
was at a distance between 2 and 7mm, which indicates higher
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bone volume in this section (Figure 10(c)). Calcium concen-
tration in the tibia was greater in Met 8 (Figure 10(d)) and,
similarly, phosphorus deposition (Figure 10(e)). Moreover,
we observed increased tibia porosity in the control group,
especially at a distance between 4 and 5mm (Figure 10(f)).
4. Discussion
Recently, more emphasis is being paid on investigating the
multidirectional action of metformin in vivo and in vitro.
While commonly known as an antidiabetic drug, metformin
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is recognized not only as a hypoglycemic agent, but also as
a potential geroprotector, a drug that protects against the
aging process [34]. It has been previously demonstrated that
metformin increases the lifespan ofmice [2] and enhances the
viability and proliferative activity of mesenchymal stromal
stem cells [35]. Thus, its application as an antiaging drug
in part follows the hypothesis that “we are as old as our
adult stem cells are.” The antiaging effects of metformin
are most likely explained by the upregulation of circulating
insulin-like growth factor-1 (IGF-1) in peripheral blood that
has been recognized as a crucial factor in the context of
longevity [36]. Bearing in mind the fact that mesenchymal
stem cells are also partially linked with longevity by their
ability to divide, proliferate, and eventually differentiate to
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replace a damaged tissue [37], it is reasonable to investigate
the effects of metformin on the differentiation potential of
endogenousMSCs, derived frommetformin-treated animals.
The aim of the present study was to investigate how met-
formin administration affects the osteogenic and adipogenic
differentiation potential of ASCs isolated from healthy mice
that previously received oral metformin supplementation for
8 weeks, with a dose that is recommended formice with DT2.
Additionally, bearing in mind the divergent data concerning
the effects of metformin on bone mineral density and bone
regenerative ability, we also focused on the evaluation of bone
density of healthy mice (without performing bone defects)
treated with metformin. We found that ASCs derived from
the 8-week metformin- (Met 8-) treated animals present dif-
ferent osteogenic and adipogenic differentiation potentials,
with cells obtained from the Met 8 group presenting with
more osteogenic than adipogenic character.
As observed in our study, metformin administration has
an important influence on ASCs morphology, proliferation
rate, and osteogenic/adipogenic differentiation ability, all of
which are essential features of tissue regeneration. Recently
published data by our group revealed that metformin affects
stromal stem cells’ proliferative activity in a dose-dependent
manner [19]. We demonstrated that metformin increases
the proliferative activity of BMSCs and mouse embryonic
fibroblast cell line Balb/3T3 after 48 h of culture, when 1mM
of metformin supplementation was used [19]. Gao et al.
[38] have demonstrated that BMSCs treated in vitro with
100 𝜇M metformin responded with an increase in prolifera-
tive activity. In turn, Śmieszek et al. [19] demonstrated that
ASCs, compared to BMSCs, are more sensitive to metformin
administration in vitro and thus even lower concentrations
of 1mM metformin resulted in decreased ASCs prolifera-
tive activity. Moreover, it was previously demonstrated that
metformin administered orally through 5 weeks at a dose of
100mg/day decreases expression of Ki-67 and osteopontin
(OPN) in subcutaneous adipose tissue. The inhibitory effect
of metformin on stromal stem cells has been explained
by the activation of adenosine 5-monophosphate-activated
protein kinase (AMPK) and inhibition of multiple molecular
signaling pathways, which are important in protein synthesis
control [33, 39].
In the current study, we found that prolonged adminis-
tration of metformin (8 weeks) at a concentration equal to
2.8mg/day in mice increases the viability and proliferative
activity of ASCs and shortens their PDT. Simultaneously,
we observed decreased activity of the senescence markers
caspase-3 and 𝛽-galactosidase in ASCs isolated from the
Met 8 group in comparison to the control group cells.
Thus, metformin supplementation may be a potential option
for overcoming the detrimental effects of aging on ASCs
and might be considered in the pretransplantation period,
especially in older patients, to enhance the effects of ASC
based regenerative therapies.
Furthermore, we found that ASCs derived from Met 8
groupwere characterized by elevated synthesis ofmembrane-
derived vesicles (MVs) observed during electronmicroscopy.
As previously demonstrated by Ratajczak [40], MVs are rich
in a broad range of growth factors that supports regenerative
processes. MVs have also been demonstrated to be involved
in intercellular signaling, and thus the elevated secretion of
MVs by the cells derived from the Met 8 group might lead to
improvement of regenerative abilities. Besides elevated MVs
secretary activity, the ASCs derived from the Met 8 group
were characterized by the development of extensive network
of filopodia that transferred the MVs between the cells, as
well as a robust net of lamellipodia. These structures play a
crucial role in promoting both cell migration and extension.
Moreover, filopodia are involved in cellular processes like
wound healing and guidance towards a chemoattractant,
whichmakes them a valuable characteristic of cells to be used
for regenerative medicine [41]. Overall, our obtained data
indicated elevated cytophysiological activity of ASCs derived
from the Met 8 group that, from a regenerative point of view,
seems to be fundamental.
Moreover, to investigate whether metformin administra-
tion affects the oxidative status of MuASC, we evaluate the
levels of ROS and NO in those cells. Beyond its antidiabetic
activity justifying its use in the treatment of the type 2
diabetes, metformin has been shown to exhibit antioxidant
properties. As it was shown by Mahrouf et al. [15] metformin
reduced intracellular ROS production in aortic endothelial
cells stimulated by a short incubation with high levels of
glucose.Moreover, data presented byAlgire et al. [42] showed
previously unrecognized inhibitory effects of metformin on
ROS production and somatic cell mutation, providing a
novel instrument for the reduction in cancer risk. Recently,
the actual mechanism underlying the antioxidative effect of
metformin was discovered. As it was shown by Hou et al.
[43], metformin induced Trx expression through activation
of AMPK-FOXO3 pathway, which in consequence led to
reduced intracellular ROS levels. Our own data confirmed
antioxidative effect of metformin as we observed decreased
ROS and NO in MuASC from Met 8 group and simulta-
neously improved antioxidant defense originated from SOD
activity. Obtained data provide a valuable information in the
contexts of diabetes treatment as increased ROS production
plays a key role in the onset and development of microvas-
cular and macrovascular complications in patients with
diabetes. Moreover, targeting endogenous ROS production
may improve ASC metabolism and proliferative potential,
making them more efficient tool in cellular therapy [44, 45].
Recently, it has been thought that metformin might
improve the osteogenic differentiation potential of stromal
stem cells and thus find an application in pharmacotherapy
in the course of the bone healing process. Our results support
this hypothesis and suggest several possible applications of
metformin in regenerative medicine. Firstly, metformin can
be used orally before collection of adipose tissue for isolation
of ASCs for clinical application, or metformin might be
used as an active agent that may be added to the culture
environment to increase activity of ASCs before patient
transplantation. Such supplementation might be especially
useful in the elderly, as it has been previously established that
osteogenic differentiation potential of ASCs declines with age
[46–48]. Furthermore, the addition of proper concentrations
of metformin in various types of biomaterials used for bone
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reconstruction may, through release into the intercellular
space, increase the bone healing process.
The above applications of metformin are also supported
by previously published data. It has been reported that
metformin can induce MC3T3-E1 osteoblastic cell differen-
tiation and bone matrix synthesis via AMPK activation and
subsequent induction of endothelial nitric oxide synthase
(eNOS) and bone morphogenetic protein-2 (BMP-2) expres-
sion [17, 18]. Metformin was also found to regulate Small
Heterodimer Partner (SHP) in MC3T3-E1 cells, an orphan
nuclear receptor that stimulates osteoblast differentiation and
affects osteoblastic bone formation by interacting with the
transcription factor Runx2 [49].
In our study, we found that 8 weeks of metformin admin-
istration in healthy mice resulted in an elevated osteogenic
differentiation potential of ASCs, with simultaneous inhibi-
tion of their adipogenic differentiation ability.Thematuration
of ASCs into osteoblasts is pivotal for fracture healing and the
osseointegration of bone-anchored implants, as well as the
general bone turnover process.The osteogenic differentiation
is regulated by a number of key factors and signaling
pathways. Commonly used as markers, at both gene and
protein levels, are BMP-2, OPN, and OCL. Here we found,
on both levels, elevated expression of BMP-2, OPN, and
OCL in cells derived from the Met 8 group. Interestingly,
on the last day of experiment, we observed that extracellular
forms of those proteins were upregulated in the Met 8, which
indicates much robust osteogenic differentiation process in
that group. As the mRNA levels are usually analyzed during
the early phases of osteogenic differentiation, we observed
only slight differences in BMP-2, OPN, and OCL expression
between investigated groups. In turn, the development of
large, mineralized osteonodules was also observed in Met 8
group. As such, our findings support the concept that stromal
stem cells, under the systemic influence of metformin, might
have wide application for use in bone healing procedures.
Our results stand in good agreement with the work by
Shah et al. [50] and Zhen et al. [51], which showed that
the proosteogenic action of metformin was possibly via
stimulation of Runx2 and production of IGF-1. On the other
hand, Wu et al. [52] demonstrated no effect of metformin
on osteogenic differentiation potential of BMSCs. Kasai et al.
[53], usingMC3T3-E1 cells and primary osteoblasts, observed
no matrix mineralization after metformin supplementation.
However, both of the above mentioned studies were per-
formed on an in vitro model using different doses of met-
formin. Along with the elevated osteogenic differentiation
potential, we observed inhibition of the adipogenic differenti-
ation ability of the ASCs isolated from both of the metformin
groups. In both of these groups, the cells were characterized
by a reduced proliferation activity. Furthermore, the cells did
not develop the typical morphological picture for adipogenic
differentiation. These results correlate with the findings of
Nicpoń et al. [37], who also observed an inhibitory effect of
metformin on adipogenic differentiation potential.
Besides finding that prolonged administration of met-
formin has a proosteogenic action, we also found that it
has an impact on cortical bone density, as well as on
medullary cavity volume.The combined investigation of 𝜇CT
and energy dispersive X-ray spectroscopy (EDX) revealed
a strong correlation between calcium/phosphorus level and
trabecular bone density. Our data is in agreement with the
findings of Sedlinsky et al. [25], who observed that oral
metformin application improves bone lesion regeneration in
both control and diabetic rats. Moreover, the authors demon-
strated that metformin administration enhanced the expres-
sion of osteoblast-specific transcription factor Runx2/Cbfa1
and activated AMPK in a time-dependent manner [25].
However, Jeyabalan et al. [54] demonstrated no significant
differences in cortical and trabecular bone architecture in
metformin-treated rodents (rat and mice after ovariectomy)
compared to controls. Furthermore, the authors showed that
metformin had no effect on bone resorption but reduced the
bone formation rate in trabecular bone. Future studies should
further assess the in vivo effects of metformin on bone.
5. Conclusions
Our results demonstrate that orally administratedmetformin
in healthy mice enhances the osteogenic differentiation
potential of ASCs, which results in an elevated expression
and secretion of BMP-2, OCL, and OPN. Additionally,
we observed that metformin supplementation significantly
reduced oxidative stress in MuASC and simultaneously
increased SOD activity. Moreover, the development of highly
mineralized osteonodules in vitro is enhanced by systemic
metformin administration. Finally, we found that 8-week
metformin supplementation leads to increased tibial bone
density in mice. Our results shine a promising light on the
potential application of metformin as an auxiliary strategy
in healthy individuals to enhance ASCs obtained for clinical
application.
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